SGD Pharma continues customer-led innovation with range extension for Sterinity Ready-to-Use molded glass vials: adds amber 50ml size ISO and EasyLyo in Tray
SGD Pharma extends Sterinity molded glass vial platform, with the introduction of amber glass 50ml.
Worldwide glass primary packaging supplier SGD Pharma announces the continued expansion of its Ready-to-Use (RTU) Sterinity molded glass vial platform with the introduction of amber glass 50ml volume option in Tray, now available ex-stock.
The addition of 50ml amber molded glass vials to the Sterinity platform,
developed at industrial scale by a leading molded glass
manufacturer, allows global pharmaceutical companies to
accelerate the time-to-market of their high-value parenteral drugs with an RTU
primary packaging solution for large brimful capacities, for which molded glass
has historically been the preferred option.
Alexander
Bautista, Product Manager Sterinity Platform, confirms: “Not only is our
Sterinity 50ml RTU vial now also available in amber glass – which protects
sensitive drugs from the harmful effects of light– but we are able to offer
customers the immediate lead times that are currently not available elsewhere for Type I vials in large brimful capacities. The Sterinity 50ml vials in both amber and
flint versions are already validated according to Good Manufacturing Practice
(GMP) standards and compliant with US and European Pharmacopoeias, and the DMF
(drug master files) will be available in May 2021, making this the optimal
pharmaceutical packaging container choice for drugs from early development
through to commercial phases. Our global customers are reassured that their
time-to-market will not be impacted by the stock availability of 50ml RTU molded glass vials.”
The range extension for the Sterinity
platform answers the potential
need of the pharmaceutical
industry to alleviate any supply chain pressures for parenteral
primary packaging materials. Having a reliable secondary supplier to provide
high-quality alternative packaging options helps to mitigate supply chain risk
and ensure Business Continuity in the event of shortages, which is facilitated
by the U.S. Food and Drug Administration(FDA)’s March 2021 Guidance for
Industry: COVID-19 Container Closure System and Component Changes: Glass Vials
and Stoppers.1 This guidance combines the
various documentation issued in the past to support SGD Pharma’s customers in any
change in vial type.
Molded
glass represents approximately 40% of the injectable vials market and is
becoming an increasingly popular solution: its higher mechanical resistance
reduces the risk of breakages during fill/finish and safeguards against harsh
processing conditions such as lyophilization, while improved chemical
performance minimizes extractables and particle contamination to meet United
States Pharmacopoeia (USP) <660> and USP <1660> guidelines.
The robust mechanical and chemical resistance of molded
glass makes the SGD Pharma’s 50ml ISO version an optimum solution for hazardous
liquids like cytotoxic drugs. The 50ml EasyLyo version is an optimized solution
for sensitive drugs manufactured through lyophilization/freeze drying, such as
some oncological treatments. The Tray and its secondary packaging design are a
state-of-the-art solution that eliminates glass-to-glass contact, reducing the
risk of particles contamination while granting the sterility and physical integrity
of each vial.
The
Sterinity platform, which already included 20–25ml EasyLyo in Tray (both flint and amber) and
now 50ml ISO/EasyLyo in Tray (both flint and amber), offers high
quality pre-sterilized Type I molded glass to speed up aseptic filling
processes and reduces time-to-market
for high value parenteral drugs.
SGD Pharma was the first molded glass manufacturer to offer
RTU vials for injectable drugs. Its long-serving partnership with Stevanato
Group has enabled the company to introduce 50ml amber glass vials powered by SG EZ-fill®
– an
industry-recognized secondary packaging platform that supports end-to-end RTU
processes. Upfront washing, depyrogenation, and sterilization steps are
taken care of, with RTU Type I molded glass vials arriving in Trays or in Nest
& Tubs ready for manual, semi-automatic, or automating fill/finish, allowing
pharma companies to focus on core business activities to expedite product launches.
Large size amber glass RTU format vials add to the extensive
Sterinity range, providing the pharma industry with access to 20ml, 25ml and 50ml
vials available ex-stock and a reliable supply source for primary packaging.
This range extension in amber is the first of several to be announced by SGD
Pharma in 2021, including the upcoming 100ml ISO RTU in Tray and the 20ml
EasyLyo in Nest & Tub.
For more
information about RTU molded glass vials from SGD Pharma, please register for
our webinar here or download our white paper here.
References:
1.
COVID-19 Container Closure System and Component
Changes: Glass Vials and Stoppers, U.S. Food and Drug Administration, March
2021. https://www.fda.gov/media/146428/download

Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance